Additionally, Syros Pharmaceuticals has utilized its gene control platform to identify acute myeloid leukemia patients and subgroups of myelodysplastic syndrome with SEs of RARA or IRF8 genes and discovered biomarkers that can recognize these SEs. This evidence concerns the gene IRF8 and acute myeloid leukemia.